Teresa Nabais

Teresa Nabais

Auto-generated profile, based on publicly available information

Teresa Nabais

Laboratory of Applied Pharmacokinetics and Bioinformatics The Saban Research Institute Children's Hospital Los Angeles Los Angeles California USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
TNT. Nabais
T. Nabais
FBFabien Brouillet
Fabien Brouillet
SKS. Kyriacos
S. Kyriacos
MMM. Mroueh
M. Mroueh
PSP. Amores da Silva
P. Amores da Silva
LCL. Cartilier
L. Cartilier

12 December 2020 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
EOEtan Orgel
Etan Orgel
TNTeresa Nabais
Teresa Nabais
CDChristopher Douglas
Christopher Douglas
SMSteven D. Mittelman
Steven D. Mittelman
MNMichael Neely
Michael Neely

8 April 2014 in ISRN Pharmaceutics
Verified
Journal Article
Open access
PDF file
TNTeresa Nabais
Teresa Nabais
GLGrégoire Leclair
Grégoire Leclair
Substituted amylose (SA) polymers were produced from high-amylose corn starch by etherification of its hydroxyl groups with chloroacetate. Amorphous high-amylose sodium carboxymethyl starch (HASCA), the resulting SA polymer, was spray-dried to obtain an excipient (SD HASCA) with optimal binding and sustained-release (SR) properties. Tablets containing different percentages of SD HASCA and tramadol hydrochloride were produced by direct compression and evaluated for dissolution. Once-daily and twice-daily SD HASCA tablets containing two common dosages of tramadol hydrochloride (100 mg and 200 mg), a freely water-soluble drug, were successfully developed. These SR formulations presented high crushing forces, which facilitate further tablet processing and handling. When exposed to both a pH gradient simulating the pH variations through the gastrointestinal tract and a 40% ethanol medium, a very rigid gel formed progressively at the surface of the tablets providing controlled drug-release properties. These properties indicated that SD HASCA was a promising and robust excipient for oral, sustained drug-release, which may possibly minimize the likelihood of dose dumping and consequent adverse effects, even in the case of coadministration with alcohol.